{"version":"1.0","provider_name":"Institut f\u00fcr Humangenetik","provider_url":"https:\/\/www.humangenetik-umg.de\/en\/","title":"Prospects of estrogen receptor \u03b2 activation in the treatment of castration-resistant prostate cancer - Institut f\u00fcr Humangenetik","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"jMH8d2anxT\"><a href=\"https:\/\/www.humangenetik-umg.de\/en\/castration-resistant-prostate-cancer\/\">Prospects of estrogen receptor \u03b2 activation in the treatment of castration-resistant prostate cancer<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.humangenetik-umg.de\/en\/castration-resistant-prostate-cancer\/embed\/#?secret=jMH8d2anxT\" width=\"600\" height=\"338\" title=\"&#8220;Prospects of estrogen receptor \u03b2 activation in the treatment of castration-resistant prostate cancer&#8221; &#8212; Institut f\u00fcr Humangenetik\" data-secret=\"jMH8d2anxT\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","description":"In a collaborative study, researchers at the Departments of Urology and Experimental Endocrinology, the Institute of Pathology and the Institute of Human Genetics of the University Medical Center G\u00f6ttingen (UMG) gained new preclinical data on the treatment of castration-resistant prostate cancer (CRPC). Advanced prostate cancer can progress to CRPC, and to date no curative treatment [&hellip;]"}